Skip to main content
The Egyptian Heart Journal

Table 2 M-mode echocardiography parameters in the study patients

From: Cardioprotective effects of deferoxamine in acute and subacute cardiotoxicities of doxorubicin: a randomized clinical trial

Parameters

Mean ± SD

P-value

 

Group 1 (n = 20)

Group 2 (n = 20)

Group 3 (n = 20)

Groups1 & 2

Groups2 & 3

Groups1 & 3

ANOVA

IVSD

0.72 ± 0.29

0.69 ± 0.18

0.71 ± 0.20

0.695

0.792

0.853

0.916

LVIDD

3.97 ± 0.83

3.84 ± 0.43

29.17 ± 97.61

0.618

0.359

0.326

0.401

LVPWD

0.68 ± 0.21

0.72 ± 0.16

0.69 ± 0.18

0.600

0.606

0.956

0.843

EDV

73.14 ± 37.80

63.80 ± 19.01

69.20 ± 20.35

0.428

0.477

0.725

0.670

IVSS

1.06 ± 0.47

0.89 ± 0.22

1.03 ± 0.30

0.236

0.184

0.859

0.424

LVIDS

2.36 ± 0.56

2.35 ± 0.34

2.20 ± 0.48

0.991

0.363

0.437

0.620

LVPWS

0.80 ± 0.15

0.80 ± 0.25

0.83 ± 0.18

0.990

0.761

0.672

0.920

ESV

21.16 ± 11.50

19.99 ± 6.79

17.70 ± 9.51

0.741

0.477

0.376

0.606

SV

52.17 ± 28.16

43.78 ± 16.81

52.17 ± 15.26

0.357

0.178

1.000

0.493

EF

71.50 ± 8.12

68.00 ± 10.27

75.52 ± 8.59

0.323

0.045

0.198

0.098

FS

27.57 ± 17.91

15.66 ± 49.80

11.79 ± 45.36

0.722

0.481

0.181

0.233

  1. Group 1: control group; group 2: intervention with deferoxamine 10-times the doxorubicin dose; group 3: intervention with deferoxamine 50 mg/kg
  2. IVSD Interventricular septal thickness in diastole, LVIDD Left ventricular internal dimension at end-diastole, LVPWD Left ventricular posterior wall in diastole, EDV End d diastolic volume, LVPWS Left ventricular posterior wall in systole, IVSS Interventricular septal thickness in systole, LVIDS Left ventricular internal dimension at end systole, ESV End-systole volume, SV Stroke volume, EF Ejection fraction, FS Fraction shorten
Back to article page